Antengene - Model XPOVIO - Multiple Myeloma (MM) Selinexor
Multiple myeloma is caused by the dysregulated proliferation of plasma cells, characterized by the proliferation of monoclonal plasma cells that results in an overabundance of monoclonal immunoglobulin or its fragment (M protein). Clinical manifestations of MM include hypercalcemia, renal insufficiency, anemia, and the destruction of the bone. 1,2 MM primarily occurs in the elderly population. In the Chinese population, MM is the second most common hematologic malignancy, 3,4 with a median age of onset of 59 years1 and an incidence rate of 1.46 per 100,0004 that is lower than that of western countries. Although MM remains an incurable disease, the introduction of new therapies and diagnostic tools have led to significant advances in the clinical management of MM. The current standard of care therapies for MM include proteasome inhibitors, immunomodulatory agents, monoclonal antibodies and XPO1 inhibitors.
-
Most popular related searches
Customer reviews
No reviews were found for Antengene - Model XPOVIO - Multiple Myeloma (MM) Selinexor. Be the first to review!